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A B S T R A C T
The widely used anticholesterolemic drugs statins decrease the synthesis of cholesterol and the
isoprenylation and activity of small G-proteins such as Ras and Rho, the effectors of which are often
critical in cell proliferation. Thanks to this property, it has been hypothesized that statins may have anti-
tumor activities. We investigated this issue in BALB-neuT mice, which developed Her2/neu-positive
mammary cancers with 100% penetrance, and in TUBO cells, a cell line established from these tumors.
Contrary to the mammary glands of BALB/c mice, the tumor tissue from BALB-neuT animals had
constitutively activated Ras and ERK1/2. These were reduced by the oral administration of atorvastatin,
but the statin did not prevent tumor growth in mice nor reduce the proliferation of TUBO cells,
although it lowered the activity of mevalonate pathway and Ras/ERK1/2 signaling. By decreasing the
mevalonate pathway-derived metabolite geranylgeranyl pyrophosphate and the RhoA/RhoA kinase
signaling, atorvastatin activated NF-kB, that sustained cell proliferation. Unexpectedly Her2-positive
cells were much more sensitive to the inhibition of RhoA-dependent pathways than to the suppression of
Ras-dependent pathways elicited by atorvastatin. Only the simultaneous inhibition of RhoA/RhoA-
kinase/NF-kB and Ras/ERK1/2 signaling allowed the statin to decrease tumor cell proliferation.
Our study demonstrates that Her2-positive mammary cancers have redundant signals to sustain their
proliferation and shows that statins simultaneously reduce the pro-proliferative Ras/ERK1/2 axis and
activate the pro-proliferative RhoA/RhoA-kinase/NF-kB axis. The latter event dissipates the antitumor
efﬁcacy that may arise from the former one. Only the association of statins and NF-kB-targeted therapies
efﬁciently decreased proliferation of tumor cells.
  2011  Elsevier  Inc.  
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Statins, which inhibit the 3-hydroxy-3-methylglutaryl coen-
zyme A reductase (HMGCoAR; EC 1.1.1.34) enzyme, are the most
effective drugs in the reduction of intracellular synthesis of
cholesterol [1]. They also decrease the synthesis of isoprenoids,
such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyro-
phosphate (GGPP), impairing the isoprenylation and activity of small
G-proteins, like Ras and Rho. When isoprenylated, monomeric G-
proteins bind and hydrolyse GTP, activating downstream effectors* Corresponding author at: Department of Genetics, Biology and Biochemistry,
Via Santena 5/bis, 10126 Torino, Italy. Tel.: +39 11 6705851; fax: +39 11 6705845.
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Open access under CC BY-NC-ND license.which in turn may modulate cell proliferation, cytoskeleton
remodeling, motility and angiogenesis [2]. High expression of the
enzymes of the mevalonate pathway has been found in human
breast cancer samples and has been correlated with the Ras-driven
oncogenic transformation [3].
By preventing the activation of Ras/Rho proteins, it has been
proposed that statins may exert pleiotropic beneﬁts on the
cardiovascular apparatus, as well as on diseases of the colon,
lung, kidney, bone and central nervous system; for the same
reasons they have also been proposed as potential adjuvant drugs
in anticancer therapy [4]. In different experimental models statins
have reduced tumor cell proliferation [5–7] and enhanced the
cytotoxic efﬁcacy of conventional chemotherapeutic drugs [8,9].
Few and conﬂicting data exist about the efﬁcacy of statins in
preventing tumor onset: atorvastatin has not decreased the
incidence of methylnitrosourea-induced breast cancers in rats
[10]; in humans some epidemiologic evidence has hypothesized a
positive correlation between the long term use of statins and the
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reduction of the incidence of breast malignancies in patients taking
HMGCoAR inhibitors [12]. Her2-positive breast tumors represent
20–30% of total breast cancers and are often associated with poor
prognosis and chemo-radio-resistance [8]. Following the constitu-
tive activation of the Her2 downstream transducers, which include
the Ras/Raf/mitogen-activated kinase (MAPKs) pathway and the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, these tumors
are characterized by a high proliferation rate and resistance to
apoptosis [8,13]. An active mevalonate pathway seems critical for
the growth of Her2-positive tumors: indeed the amounts of plasma
membrane cholesterol affect Her2 conformation and activity and
the levels of isoprenoid dolichol regulate the Her2 glycosylation.
Furthermore, an adequate supply of FPP is mandatory for the
activity of Ras protein and for the subsequent activation of Ras-
downstream effectors [8]. The association of statins and speciﬁc
Her2-targeting therapies has achieved a good anti-proliferative
effect [8,9]. However, it has also been reported that statins increase
the activity of the MAPK members extracellular signal-regulated
kinase 1/2 (ERK1/2) [14], which induces pre-invasive lesions in the
mammary epithelium [15].
BALB/c mice transgenic for the transforming rat Her2/neu
oncogene under the transcriptional control of the mouse
mammary tumor virus promoter (BALB-neuT mice), develop
breast cancer with 100% penetrance [16]. Starting from atypical
hyperplasia (at week 3), mammary glands display at 8 weeks
multiple in situ carcinomas, which become invasive tumors
between weeks 17 and 22 [17].
In this study we investigated the effects of atorvastatin, at a
dose equivalent roughly to 40 mg/day in human treatment, that
falls in the range adopted for anticholesterolemic therapy (10–
80 mg/day) [18], on the growth of breast tumors in BALB-neuT
mice and on the pathways that are controlled by the drug in the
transformed mammary cells.
2. Materials and methods
2.1. Chemicals
Fetal bovine serum (FBS), penicillin–streptomycin (PS) and
RPMI 1640 were supplied by Sigma Chemical Co (St. Louis, MO),
plastic ware for cell culture was from Falcon (BD Biosciences
Discovery Labware, Bedford, MA). Electrophoresis reagents were
obtained from Bio-Rad Laboratories (Hercules, CA), the protein
content of cell monolayers and cell lysates was assessed with the
bicinchoninic acid kit from Sigma Chemical Co. Atorvastatin was
purchased from Sequoia Research Products (Pangbourn, UK). FTI-I
and GGTI-286 were acquired from Calbiochem (San Diego, CA).
When not otherwise speciﬁed, all the other reagents were
purchased from Sigma Chemical Co.
2.2. Cells
TUBO cells are a cloned line generated from a BALB-neuT mouse
mammary gland carcinoma and express large amounts of Her2/
neu protein [19]. Cells were cultured in DMEM with 10% v/v FBS, 1%
v/v PS in a humidiﬁed atmosphere at 37 8C and 5% CO2.
2.3. Mice and in vivo treatments
Six-week-old female BALB/c mice were supplied by Charles
River Italia SpA (Calco, Italy). Virgin female BALB-neuT mice
transgenic for the transforming activated rat Her2/neu oncogene
under the transcriptional control of the mouse mammary tumor
virus promoter were bred under speciﬁc pathogen-free conditions
by Charles River. Mice were treated according to the guide linesestablished in Guide for the Care and Use of Laboratory Animals
and in Principles of Laboratory Animal care (directive 86/609/EEC).
All the experiments were approved by the institutional Ethical
Committee.
Mice were randomly assigned to control and treatment
groups and all groups were treated concurrently. Atorvastatin
was brought into suspension in PBS at 12 mg/day (roughly
equivalent to 40 mg/day in human treatment), and a 0.2 ml
volume was administered via oral gavage. Atorvastatin admin-
istration occurred once daily, 5 days per week for 8 weeks,
starting from week 10 until week 17. Control mice were treated
with PBS only.
BALB/c mice were challenged s.c. in the right ﬂank with 0.2 ml
of a suspension containing the minimal lethal dose of TUBO cells
(105) [19].
Mice were inspected weekly to monitor the appearance of
autochthonous mammary tumors. Neoplastic masses were mea-
sured with calipers in two perpendicular diameters and the
average value was recorded. Progressively growing masses
(>1 mm mean diameter) were regarded as tumors. According to
our ethical protocol mice were killed when a ﬁrst tumor exceeded
10 mm mean diameter.
2.4. Mammary gland isolation
BALB/c and BALB-neuT mice were sacriﬁced at week 18, when
the atorvastatin treated groups were at the end of the 8 week
atorvastatin treatment period. The thoracic and abdominal
mammary glands were isolated, incubated for 48 h at 4 8C in
RNA Later (Quiagen, Hilden, Germany), drained and stored at
80 8C for 1 day and than homogenized in MLB buffer (125 mM
Tris–HCl, pH 7.4, 750 mM NaCl, 1% v/v NP40, 10% v/v glycerol,
50 mM MgCl2, 5 mM EDTA, 25 mM NaF, 1 mM NaVO4, 10 mg/ml
leupeptin, 10 mg/ml pepstatin, 10 mg/ml aprotinin and 1 mM
phenylmethanesulfonylﬂuoride, PMSF).
2.5. Mevalonate pathway activity
TUBO cells were incubated for 24 h with 1 mCi of [3H]acetate
(3600 mCi/mmol; Amersham GE Healthcare, Little Chalfront, UK),
then washed with PBS and transferred to glass microcentrifuge
tubes. The intracellular synthesis of cholesterol, FPP and GGPP was
measured by the methanol/hexane extraction method, followed by
thin layer chromatography [20]. Standard solutions of cholesterol,
FPP and GGPP (1 mg/ml; Sigma Chemical Co.) were also loaded on
the chromatography gel. After the separation, the gel was exposed
to an iodine-saturated atmosphere. Each spot was cut and
solubilised and the radioactivity incorporated measured by liquid
scintillation counting (Ultima Gold, PerkinElmer, Waltham. MA).
The results were expressed as fmol/106 cells, according to the
titration curve previously obtained.
2.6. NF-kB activity
TUBO cells and mammary gland extracts were rinsed with
0.5 ml lysis buffer A (10 mM HEPES, 15 mM KCl, 2 mM MgCl2,
0.1 mM EDTA, 1 mM PMSF, 1 mM dithiothreitol DTT, 10 mg/ml
aprotinin, 2 mg/ml leupeptin, 0.1% v/v NP40, pH 7.6), incubated for
10 min on ice, vortexed and centrifuged for 30 s at 13,000  g to
pellet nuclei, which were re-suspended in 0.2 ml wash buffer B
(25 mM HEPES, 2 mM KCl, 0.1 mM EDTA, 1 mM PMSF, 1 mM DTT,
10 mg/ml aprotinin, 2 mg/ml leupeptin, pH 7.6) and incubated at
4 8C for 10 min. An equal volume of buffer C (25 mM HEPES,
0.1 mM EDTA, 20% v/v glycerol, pH 7.6) was added and after 10 min
the mix was centrifuged at 13,000  g for 15 min at 4 8C. The
activity of NF-kB in the supernatants containing the nuclear
Fig. 1. Effect of atorvastatin on Ras, ERK1/2 and Akt activity in mammary glands of
BALB/c and BALB-neuT mice. Transgenic BALB-neuT mice (n = 5) were treated
with atorvastatin (AT) for 8 weeks as reported in Section 2; then mammary glands
were isolated for protein extraction. An equal number of transgenic BALB-neuT
mice and wild type BALB/c mice were used as control (CTRL). The experiment was
replicated three times. A. Ras-GTP pull down. Mammary gland homogenates were
lysed and the expression of Ras-GTP and total Ras was analyzed as described in
Section 2. The ﬁgure is representative of 3 mice in each group of treatment; similar
results were obtained in the other animals of each group; B. Western blot
detection of phospho-ERK1/2, ERK1/2, phospho-Akt, Akt. Mammary gland
homogenates were analyzed by Western blotting with an anti-phospho-
(Thr202/Tyr204, Thr185/Tyr187)-ERK1/2, an anti-ERK1/2, an anti-phospho-
Ser(473)-Akt or an anti-Akt antibody, as reported in Section 2. The expression
of GAPDH was used to check the equal protein loading. The ﬁgure is representative
of 3 mice in each group of treatment; similar results were obtained in the other
animals of each group.
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(Active Motif, Rixensart, Belgium), adding 1 pmol of the biotiny-
lated NF-kB consensus site 50-GGGACTTTCC-30 to 10 mg of nuclear
extracts and following the manufacturer’s instructions. The
absorbance at 450 nm was measured with a Packard EL340
microplate reader (Bio-Tek Instruments, Winooski, VT). For each
set of experiments, a blank was prepared with distilled water, and
its absorbance was subtracted from that obtained in the presence
of nuclear extracts. To assess the procedure speciﬁcity, a
competition assay was performed by adding 40 pmol of wild type
non-biotinylated oligonucleotide to nuclear extracts derived from
TUBO cells treated 24 h with 20 mg/ml lipopolysaccharide from E.
coli (Sigma Chemical Co.). Data were expressed as mU absorbance/
mg cell proteins.
2.7. Cell proliferation assays
TUBO cells were seeded at a density of 5  103/ml into ﬂat
bottom 96-well microplates in 100 ml complete DMEM medium.
After 6 h the medium was replaced with serum-free medium and
cells were incubated 24 h with the appropriate stimuli (2.5, 20, 50,
100 and 200 mM atorvastatin; 10 mM parthenolide; 50 mg/ml
mytomicin-C). After 12 h, 10 ml Br-deoxyuridine (Br-dU; Cell
Proliferation ELISA BrdU kit, Roche, Basel, Switzerland) was added
to every well and after a further 12 h, cell proliferation was
assessed, reading the sample absorbance at 370 nm, in accordance
with the producer’s instructions. Growth of TUBO cells was
represented as optical density (O.D.). The proliferation index was
calculated as the ratio between the O.D. of each other experimental
point and the O.D. obtained in the presence of the higher
concentration (200 mM) atorvastatin.
2.8. G-proteins activity
Ras-GTP binding, considered an index of monomeric G-protein
activation [21], was measured in pull-down assays using the Ras
Assay Reagent (Raf-1 RBD, agarose conjugate; Millipore, Billerica,
MA), as reported in [22]. RhoA activation was detected with the G-
LISATM RhoA Activation Assay Biochem Kit (Cytoskeleton Inc.,
Denver, CO), according to the manufacturer’s instructions. Data
were expressed as mU absorbance/mg cell proteins.
2.9. RhoA kinase activity
RhoA kinase activity was measured using the CycLex Rho Kinase
Assay Kit (CycLex MBL International, Woburn, MA), a single site
binding immunoassay, as previously reported [22]. Data were
expressed as mU absorbance/mg cell proteins.
2.10. Western blot analysis
TUBO cells and mammary gland homogenates were lysed in the
MLB buffer, sonicated on crushed ice (with two 10 s-bursts, using a
Hielscher Ultrasonics GmbH Instrument, Teltow, Germany) and
centrifuged at 13,000  g for 10 min at 4 8C. 20 mg cell lysates were
subjected to SDS-PAGE, transferred to polyvinylidene ﬂuoride
membrane sheets (Immobilon-P, Millipore) and probed with the
following antibodies: anti-phospho-(Thr202/Tyr204, Thr185/
Tyr187)-extracellular signal-regulated kinase 1/2 (ERK1/2; diluted
1:1000 in TBS-milk 5% w/v, Millipore); anti-ERK1/2 (diluted 1:500
in TBS-milk 5% w/v, Millipore); anti-phospho-Ser(473)-Akt (dilut-
ed 1:200 in TBS-milk 5% w/v, Millipore); anti-Akt (diluted 1:500 in
PBS–BSA 1% w/v, Santa Cruz Biotechnology Inc., Santa Cruz, CA);
anti-Ras (diluted 1:250 in TBS-milk 5% w/v, Millipore); anti-RhoA
(diluted 1:250 in PBS–BSA 1% w/v, Santa Cruz Biotechnology Inc.);
anti-phospho-Ser(176/180)-IKKa/b (diluted 1:500 in PBS–BSA 1%w/v, Cell Signaling Technology Inc., Danvers, MA); anti-IKKa/b
(diluted 1:500 in PBS–BSA 1% w/v, Santa Cruz Biotechnology Inc.);
anti-IkB-a (diluted 1:500 in PBS–BSA 1% w/v, Santa Cruz
Biotechnology Inc.); anti-glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH; diluted 1:500 in PBS–BSA 1% w/v, Santa Cruz
Biotechnology Inc.). Membrane was washed in TBS-Tween 0.1% v/
v, subjected for 1 h to a peroxidase-conjugated anti-rabbit or anti-
mouse IgG (diluted 1:3000 in TBS-milk 5% w/v, Bio-Rad), washed
again with TBS-Tween 0.1% v/v. Proteins were detected by
enhanced chemiluminescence (PerkinElmer).
In vitro IKK kinase assay was performed as reported previously
[22], using an anti-IKKg antibody (diluted 1:200 in PBS–BSA 1% w/
v, Santa Cruz Biotechnology Inc.) to isolate the IKK complex.
100 mg of the immuno-precipitated proteins were incubated with
1 mM ATP and 30 mg of immunopuriﬁed IkB-a protein. Reaction
was carried over at 30 8C for 30 min and stopped with 30 ml of
Laemli buffer (60 mM Tris–HCl, pH 6.8, 2% w/v SDS, 10% v/v
glycerol, 5% w/v b-mercaptoethanol, 0.01% w/v bromophenol
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an anti-IkB-a antibody, to check the total amount of IkB-a loaded
in each assay, and with an anti-phospho-Ser(32)-IkB-a antibody
(diluted 1:250 in PBS–BSA 1% w/v, Santa Cruz Biotechnology Inc.),
to detect the amount of IkB-a phosphorylated by the active IKK
complex.
The densitometric analysis of Western blots was performed
using ImageJ software (http://rsb.info.nih.gov/ij/) and was
expressed as arbitrary units, where ‘‘1’’ is the mean band density
of untreated cells.
2.11. RhoA silencing
1  105 TUBO cells were treated for 6 h with 1 ml siRNA
transfection medium (Santa Cruz Biotechnology Inc.), containing
5 ml siRNA transfection reagent (Santa Cruz Biotechnology Inc.)
and 50 pmol RhoA siRNA (Santa Cruz Biotechnology Inc.). In each
set of experiments, one dish was treated with 50 pmol of Control
siRNA-A (Santa Cruz Biotechnology Inc.), a non-targeting 20- to 25-
nucleotide siRNA designed as a negative control, instead of RhoA
siRNA. After 72 h the silencing efﬁcacy was veriﬁed by WesternFig. 2. Effect of atorvastatin on the growth of Her2/neu over-expressing tumors. A. Tu
diameter) in mice challenged with Her2/neu over-expressing TUBO cells and treated with
TUBO mammary tumor cells and orally treated with atorvastatin administered for 8 we
signiﬁcantly different in the atorvastatin treated mice compared with the control (PBS-tr
time (days) in control and atorvastatin-treated BALB/c mice of point A. C. Graph representing
free animals, in control (n = 14) and atorvastatin-treated (n = 8) BALB-neuT mice. Chi square 
test: 1.609 (not signiﬁcant).blotting for RhoA protein. Cell toxicity was assessed by monitoring
the extracellular release of lactate dehydrogenase enzyme, as
reported [23], and was super-imposable on that of untreated cells
(not shown).
2.12. Statistical analysis
All data in text and ﬁgures are provided as means  SE. The
results were analyzed by a one-way Analysis of Variance (ANOVA).
Survival curves were analyzed by a Chi square Test and the tumor
growth was analyzed by Student’s t Test. A p < 0.05 was considered
signiﬁcant. r2 coefﬁcient in linear regression analysis was calculated
using Fig.P software (Fig.P Software Inc., Hamilton, Canada).
3. Results
3.1. Atorvastatin abolishes the activation of Ras and ERK1/2 in BALB-
neuT mice mammary gland tumors
Female BALB/c mice and BALB-neuT mice were sacriﬁced at 18
weeks of age, a time at which in BALB-neuT mammary glandsmor latency (time required from the challenge to a tumor of the indicated mean
 atorvastatin. BALB/c mice were challenged with a lethal dose (105 cells) of syngenic
eks as described in Section 2 (atorvastatin group: n = 6). Tumor diameters were not
eated) mice (control group: n = 4); B. Tumor growth (mean  SE, mm) in function of
 tumor growth in single BALB/c mice challenged with TUBO cells. D. Percentage of tumor
test: 2.160 (not signiﬁcant). E. Overall survival of BALB-neuT mice of point D. Chi square
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was treated with atorvastatin as reported in Section 2. Mammary
glands were collected and examined for the activity of the
downstream effectors of Her2/neu. The expression of total Ras did
not change between BALB/c and BALB-neuT mice (Fig. 1A), whereas
signiﬁcant differences were detected in Ras-GTP binding, an index
of Ras isoprenylation and activity [21]: Ras-GTP was in fact
undetectable in non transformed mammary glands of BALB/c mice,
but present in tumoral glands of BALB-neuT mice. Interestingly, in
BALB-neuT mice treated with atorvastatin, the activation of Ras
was prevented (Fig. 1A).
We then analyzed the expression and activity of MAPKs ERK1
and ERK2, which are downstream effectors of Ras, and of Akt,
which can also be activated independently from Ras [13]. In
keeping with the Ras-GTP activity, phosphorylated active ERK1/2
were hardly detected in BALB/c mammary glands and constitu-
tively present in tumor glands of BALB-neuT mice; again
atorvastatin strongly reduced the phosphorylation of ERK1 and
ERK2 in BALB-neuT tumor extracts (Fig. 1B). Akt was basally
phosphorylated in BALB/c mice; the phosphorylation was higher in
BALB-neuT mice and slightly reduced by the statin (Fig. 1B). The
total amount of ERK1/2 and Akt did not change under any
experimental conditions (Fig. 1B).Fig. 3. Dose-dependent effects of atorvastatin on mevalonate pathway, Ras activity and
different concentrations of atorvastatin (2.5, 20, 50, 100, 200 mM; ator) for 24 h, then sub
activity. Cells were grown in a medium containing 1 mCi of [3H]-acetate, then lysed and 
GGPP, as reported in Section 2. Data are presented as means  SE (n = 3). vs. ‘‘0’’: *p < 0.02
down assays (see Section 2). The ﬁgure is representative of 3 experiments with similar resu
units. vs. ‘‘0’’: *p < 0.005. C. Evaluation of the effects exerted by atorvastatin at different con
blocker mytomicin C (50 mg/ml) was used and yielded 190.00  10.28 O.D. Data are prese3.2. Atorvastatin administration does not inhibit the growth of
implanted TUBO cells in BALB/c mice and the spontaneous tumor
development in BALB-neuT mice
Implanted TUBO cells, a cell line established from BALB-neuT
mice mammary tumors, grow fast in wild-type BALB/c mice and
form a palpable tumor mass in about 2 weeks [25]. To evaluate the
effects of atorvastatin on the growth of implanted tumors, female
BALB/c mice were challenged s.c. with 105 TUBO cells. On the same
day, oral treatment with atorvastatin was started. No signiﬁcant
differences were observed in the growth of TUBO tumors in treated
vs. control mice (Fig. 2A and B). Only in 2/6 atorvastatin treated
mice was a delay in tumor growth observed (Fig. 2C).
Female BALB-neuT mice develop mammary tumors in all their
mammary glands [25]. In the BALB-neuT control group at least one
palpable carcinoma (>1 mm mean diameter) was evident in each
mouse by week 24 (Fig. 2D), while by week 35 a tumor mass was
palpable in all 10 mammary glands or the tumor burden was such
that the mice were sacriﬁced for ethical reasons (Fig. 2E). Oral
administration of atorvastatin from week 10 to week 17 did not
delay tumor progression in female BALB-neuT mice. All treated
mice had at least one palpable tumor by week 25 (Fig. 2D) and at 37
weeks all animals were dead (Fig. 2E). proliferation of TUBO cells. Cells were incubated in the absence (0) or presence of
jected to the following investigations. A. Measurement of the mevalonate pathway
subjected to lipid extraction to measure the rate of synthesis of cholesterol, FPP and
. B. Ras-GTP pull down. The expression of Ras-GTP and total Ras was analyzed in pull-
lts. The band density ratio between Ras-GTP and total Ras was expressed as arbitrary
centrations on the proliferation of TUBO cells. As internal control, the cell proliferation
nted as means  SE (n = 3). vs. ‘‘0’’: *p < 0.05.
C. Riganti et al. / Biochemical Pharmacology 82 (2011) 1079–108910843.3. Atorvastatin decreases the FPP levels and the Ras activity but not
the proliferation of mammary Her2-positive cancer cells
To investigate the molecular basis of atorvastatin low efﬁcacy in
preventing tumor growth, despite the reduction of the pro-
proliferative signals acting downstream Her2 oncogene (like Ras
and ERK1/2), we ﬁrst veriﬁed whether atorvastatin was able to
exert its ‘‘canonical’’ metabolic effects, that is to reduce the activity
of the mevalonate pathway in TUBO cells. The drug regularly
worked as an HMGCoAR inhibitor in our model, since it dose-
dependently reduced the de novo synthesis of cholesterol and of
the intermediate isoprenoid metabolites FPP and GGPP (Fig. 3A). In
keeping with these results, the drug also decreased the amount of
GTP-bound Ras (Fig. 3B). On the other hand, the proliferation of
TUBO cells was not affected, except in the presence of high
micromolar concentrations of atorvastatin (Fig. 3C), thus reprodu-
cing the refractoriness to the anti-proliferative effect previously
observed in vivo (Fig. 2).
3.4. In Her2-positive cancer cells atorvastatin increases the activation
of NF-kB, that is negatively correlated with the amount of isoprenoids
A correlation is known to exist between the mevalonate
pathway and the activation of the transcription factor NF-kB
[26,27]. In TUBO cells increasing concentrations of atorvastatin,
which progressively reduced the activity of the mevalonate
pathway (Fig. 3A), elicited an increasing activation of NF-kB
(Fig. 4A). Such activation was inversely correlated with the amount
of FPP (Fig. 4B) and GGPP (Fig. 4C), suggesting that isoprenoids may
exert inhibitory effects on the activity of NF-kB in TUBO cells.A
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Fig. 4. Dose-dependent effects of atorvastatin on NF-kB activation in TUBO cells.
Cells were incubated in the absence (0) or presence of different concentrations of
atorvastatin (2.5, 20, 50, 100, 200 mM; ator) for 24 h. A. NF-kB activation by
atorvastatin. The activity of NF-kB was detected in the nuclear extracts measuring
the amount of NF-kB bound to its target sequences on DNA, with a DNA binding
assay (see Section 2 for details). In the competitions assay, performed with an
excess of non-biotinylated oligonucleotide and used as a control of the assay
speciﬁcity, the activity of NF-kB in cells treated with E. coli lipopolysaccharide was
2.06  0.45 mU/mg prot. Measurements were performed in duplicate and data are
presented as means  SE (n = 3). vs. ‘‘0’’: *p < 0.001. B. Linear regression analysis
between FPP synthesis and NF-kB activity. FPP levels (Fig. 3A) were plotted vs. NF-kB
activation (expressed in A), to obtain r2 coefﬁcient. C. Linear regression analysis
between GGPP synthesis and NF-kB activity. GGPP levels (Fig. 3A) were plotted vs. NF-
kB activation (A), to obtain r2 coefﬁcient.3.5. Her2-positive cancer cells have a different sensitivity toward the
effects of atorvastatin on Ras-dependent and RhoA-dependent
pathways
Although atorvastatin decreased the rate of synthesis of FPP at
low micromolar concentrations (Fig. 3A), a clear reduction in Ras
activity was obtained only at high micromolar concentrations in
TUBO cells (Fig. 3B). According to this observation, the activity of the
Ras-downstream effectors ERK1/2 and of Akt was not affected by low
concentration (2.5 mM) atorvastatin (Fig. 5A and C). A 50 mM (Fig. 5B
and D) or a higher concentration (data not shown) of the statin was
necessary to decrease the activity of ERK1/2 and to reduce –
although to a lesser extent – the activation of Akt. Such effects were
likely to have been dependent on the diminished farnesylation of
Ras, since they were abrogated by the cell-permeable FPP analogue
farnesol and were mimicked – with a stronger potency – by the
inhibitor of farnesyl transferase FTI-I (Fig. 5B and D).
Surprisingly, 2.5 mM atorvastatin was sufﬁcient to elicit a
remarkable decrease of RhoA and RhoA kinase activity, to an extent
super-imposable on the geranylgeranyl transferase inhibitor GGTI-
286 (Fig. 6A). In parallel atorvastatin induced the activation of NF-
kB (Fig. 6B), by increasing the phosphorylation (Fig. 6C) and
activity (Fig. 6D) of IkB kinase (IKK)a/b complex and by decreasing
the amount of the inhibitor protein IkB-a (Fig. 6C). The effect of
atorvastatin on NF-kB (Fig. 6B) and on IKK/IkB-a axis (Fig. 6C) was
likely dependent on the reduced activity of RhoA, since it was lost
in the presence of the cell-permeable GGPP analogue geranylger-
aniol. On the contrary the activation of NF-kB was obtained if we
inhibited the geranylgeranyl transferase enzyme with GGTI-286
(Fig. 6B). The activation of IKK/IkB-a axis was also achieved in cells
knocked down for RhoA protein, a situation which made
geranylgeraniol devoid of effects (Fig. 6C and D). Farnesol
(10 mM for 24 h) on the contrary did not prevent the effects of
atorvastatin on NF-kB in TUBO cells (data not shown).
3.6. Atorvastatin decreases the activity of RhoA/RhoA kinase and
activates NF-kB in BALB-neuT mice mammary gland tumors
A similar pattern of RhoA-dependent activation of NF-kB was
observed in the tumor mammary glands of mice. We did not detect
any difference in the basal activity of RhoA, RhoA kinase (Fig. 7A),
IKK/IkBa proteins (Fig. 7B) and NF-kB activity (Fig. 7C) in BALB/c
and BALB-neuT animals, whereas atorvastatin signiﬁcantly re-
duced the activation of RhoA and of its downstream effector in
treated BALB-neuT mice (Fig. 7A). In parallel the drug increased the
phosphorylation of IKK, decreased the amount of the constitutively
present IkB-a (Fig. 7B) and elicited the binding of NF-kB on its
target sequences on DNA (Fig. 7C).
3.7. The simultaneous co-administration of a NF-kB inhibitor allows
atorvastatin to reduce Her2-positive cancer cell proliferation
Since NF-kB is a crucial factor for cell proliferation and survival
[28], we hypothesize that the lack of anti-proliferative effects of
atorvastatin, despite the down-regulation of Ras/MAPKs signaling,
could depend on the simultaneous activation of NF-kB with a
RhoA-dependent mechanism. We thus examined the effects of the
statin in the presence of a NF-kB inhibitor such as parthenolide,
which reduced per se the basal activity of NF-kB (Fig. 8A) and the
proliferation of TUBO cells (Fig. 8B).
If associated with parthenolide, atorvastatin – at a concentra-
tion that reduced the Ras signaling (Fig. 3B), but did not decrease
cell proliferation (Fig. 3C) – was prevented to activate the
transcription factor (Fig. 8A). Only in this condition did the drug
effectively reduce the proliferation of TUBO cells; interestingly it
had additive effects with parthenolide (Fig. 8B).
Fig. 5. Effects of low vs. high concentrations of atorvastatin on ERK1/2 and Akt activity in TUBO cells. Cells were incubated for 24 h in fresh medium (CTRL) and in the presence
of a low atorvastatin concentration (2.5 mM, AT; panel A), or of a high atorvastatin concentration (50 mM, AT), with or without farnesol (10 mM, FO), a cell-permeable analogue
of FPP (panel B). The farnesyl transferase inhibitor FTI-I (10 mM for 24 h, FTI) was added as a positive control of Ras inhibition. Cells were lysed and analyzed by Western
blotting with an anti-phospho-(Thr202/Tyr204, Thr185/Tyr187)-ERK1/2, an anti-ERK1/2, an anti-phospho-Ser(473)-Akt or an anti-Akt antibody, as reported in Section 2. The
expression of GAPDH was used to check the equal protein loading. The ﬁgure is representative of 3 experiments with similar results. C and D. The band density ratio between
pERK1/2 and total ERK1/2 and between pAkt and Akt for each experimental point of panel A and B was expressed as arbitrary units. vs. ‘‘CTRL’’: *p < 0.02.
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Cancer represents a putative ﬁeld of application for statins,
since most activities of transformed cells, such as proliferation,
matrix invasion and angiogenesis, are controlled by the isopre-
nylated small G-proteins of Ras and Rho family, that are inhibited
by statins [2].
The subgroup of Her2 overexpressing breast cancers is
particularly interesting, because one of the most active down-
stream transducers of the Her2 oncogene is Ras [8].
In our work we found that untransformed mammary glands of
BALB/c mice were devoid of active GTP-bound Ras, which was
instead detected in tumor glands of Her2-transgenic BALB-neuT
and suppressed by treatment with atorvastatin. The striking
difference in Ras activity between wild-type and transgenic mice
led us to the hypothesis that this G-protein has a prominent role in
the tumorigenesis and/or in the tumor growth in BALB-neuT mice.
In cells with constitutively activated EGF receptors, the MAPKs
signaling enhances proliferation [5]. Indeed the activation of ERK1
and ERK2 kinases in our experimental model strictly followed the
activity of Ras. The activity of the Akt signaling displayed minor
changes: phospho-Akt was detectable also in non transformed
mammary glands, was slightly increased in BALB-neuT animals
and slightly reduced by atorvastatin. These results however are not
surprising: also in Her2-negative MCF-7 cells, Akt is constitutively
phosphorylated [29], probably in consequence of the multiple
activating signals converging on kinase B, besides those dependenton Her2 and EGF receptors. By reducing Ras/ERK1/2 and Akt
activation in the mammary glands of BALB-neuT mice, atorvastatin
should have at least two requisites to reduce cells proliferation [5].
Unexpectedly, we did not observe any growth reduction of
tumors implanted in statin-treated BALB/c mice nor a delay in the
growth of the autochthonous mammary tumors in BALB-neuT
animals, a result that is in contrast with other experimental works
[5,30]. To clarify whether the lack of efﬁcacy of atorvastatin,
despite its ability to reduce the Her2-dependent signal transduc-
tion, was due to reasons residing within the tumor cell, we
investigated if the drug exerted the ‘‘classical’’ metabolic effects of
statins in the epithelial TUBO cell line, derived from the BALB-neuT
mice mammary tumors. Here atorvastatin decreased the rate of
synthesis of cholesterol, FPP and GGPP already at low micromolar
concentrations, in keeping with the statin’s Ki for HMGCoAR, that is
in nanomolar range [31]. At these concentrations atorvastatin did
not reduce the proliferation rate, but was able to increase the
activity of NF-kB, a transcription factor critical for proliferation and
inhibition of apoptosis [28]. A strong negative correlation between
isoprenoids levels and NF-kB activation was found in TUBO cells,
suggesting that statins may up-regulate NF-kB activity through the
decreases of some isoprenylated products.
The effects of statins on the NF-kB pathway are highly variable
depending on cell type [32–34]. In breast cancer cells, both
inhibitory [6] and stimulating [35] effects of statins on NF-kB
target genes have been reported. The activity of NF-kB can be
reduced by FPP [27] and GGPP [26], and in some experimental
Fig. 6. Effects of low concentration of atorvastatin on RhoA/RhoA kinase/NF-kB pathway in TUBO cells. Cells were grown 24 h in the absence (CTRL) or presence of atorvastatin
(2.5 mM, AT), geranylgeraniol (10 mM, GGO), a cell-permeable analogue of GGPP, or both. GGTI-286 (10 mM, GGTI), a speciﬁc inhibitor of geranylgeranyl transferase, was
added as a positive control of RhoA inhibition. A. Samples were subjected to ELISA assays to measure the amount of RhoA-GTP (open bars) and the activity of RhoA kinase
(hatched bars). The experiments were performed in duplicate, as described in Section 2. Data are presented as means  SE (n = 3). vs. CTRL: *p < 0.005; vs. AT: 8p < 0.01. B. NF-kB
activation. The activity of NF-kB was detected in the nuclear extracts measuring the DNA-binding capacity of NF-kB with a DNA-binding assay (see Section 2). Measurements were
performed in duplicate and data are presented as means  SE (n = 3). vs. CTRL: *p < 0.005; vs. AT: 8p < 0.05. C. TUBO cells were treated as reported above; an aliquot of cells was
subjected to RhoA silencing (RNAi RhoA), as reported in Section 2, and grown 24 h after the end of transfection in the absence (CTRL) or presence of geranylgeraniol (10 mM, GGO).
Samples were analyzed by Western blotting with an anti-RhoA, an anti-phospho-Ser(176/180)-IKKa/b, an anti-IKKa/b and an anti-IkB-a antibody, as reported in Section 2. The
expression of GAPDH was used to check the equal protein loading. The ﬁgure is representative of 3 experiments with similar results. D. IKK activity. From cell extracts incubated as
reported at point C, IKK complex was isolated by immunoprecipitation using an anti-IKKg antibody and incubated with puriﬁed IkB-a protein. The amount of IkB-a phosphorylated
by the active IKK complex was detected with an anti-phospho-Ser(32)-IkB-a antibody (pIkBa). The extracts were also probed with an antibody for total IkB-a, to check that equal
amounts of the protein were used in each kinase assay (input IkBa). The ﬁgure is representative of 2 experiments with similar results.
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malignant mesothelioma and colon cancer RhoA and RhoA
kinase negatively regulate the activity of the IKK complex, and
prevent the phosphorylation of the inhibitory protein IkB-a,
which in this way maintains NF-kB inactive in cytosol. On the
contrary, statins or RhoA silencing activate the IKK kinase and
allow NF-kB to translocate into the nucleus [22,23]. Such a RhoA-
operated inhibition of NF-kB occurred also in TUBO cells treated
with atorvastatin. Since geranylgeraniol prevented the effects of
the statin on IKK/IkB-a axis in wild-type but not in RhoA-
silenced cells, we can conclude that no geranylgeranylated
proteins other than RhoA are involved in the control of NF-kB
activation in TUBO cells.
What is most surprising is the observation that the sensitivity
to statin of Ras-dependent pathways was lower than the
sensitivity of RhoA-dependent pathways. The presence of the
constitutively active Her2 oncogene which maintains Ras in a
permanent activated status could make difﬁcult for atorvastatinto suppress such activation, except at high concentrations. The
low sensitivity of TUBO cells to drugs affecting the Her2/Ras
signaling was conﬁrmed by the observation that low micromolar
concentrations of farnesol did not reduce the activation of NF-kB
elicited by atorvastatin. On the other hand the strong negative
correlation between FPP level and NF-kB activation suggests that
also FPP, as well as GGPP, exerted a suppressive role on NF-kB.
Considering the low sensitivity of Ras-dependent pathways and
the constitutively high activation of Ras in TUBO cells, it seems
unlikely that FPP prevents the activation of NF-kB through a
further increment of Ras activity. FPP could act instead with an
indirect mechanism, e.g. being the precursor of GGPP, that
suppresses the activation of NF-kB in a RhoA/RhoA kinase-
dependent way.
If compared with other tumor histotypes [22,38], RhoA and
RhoA kinase have a very low basal activity in our Her2-positive
mammary cancer cells. Therefore, also a small reduction of RhoA
activity, such as that elicited by low micromolar concentrations of
Fig. 7. Effects of atorvastatin on RhoA, RhoA kinase and NF-kB activation in mammary glands of BALB/c and BALB-neuT mice. Transgenic BALB-neuT mice (n = 5) were treated
with atorvastatin (AT) for 8 weeks as reported in Section 2; then mammary glands were isolated for protein extraction. An equal number of transgenic BALB-neuT mice and
wild type BALB/c mice were used as control (CTRL). A. RhoA-GTP and RhoA kinase activity. Samples were subjected to ELISA assay to measure the amount of RhoA-GTP (open
bars) and the activity of RhoA kinase (hatched bars). The experiments were performed in duplicate, as described in Section 2. Data are presented as means  SE. vs. CTRL BALB-
neuT: *p < 0.005. B. Western blot detection of phospho-Ser(176/180)-IKKa/b, IKKa/b and IkB-a protein in cytosolic extracts from mammary glands. The expression of GAPDH was
used to check the equal protein loading. The ﬁgure is representative of 3 mice in each group of treatment; similar results were obtained in the other animals of each group; C. The
activity of NF-kB was detected in nuclear extracts as the capacity of the translocated NF-kB to bind its target sequences on DNA (as reported in Section 2). Measurements were
performed in duplicate and data are presented as means  SE. vs. CTRL BALB-neuT: *p < 0.05.
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molecular events downstream RhoA. Second, the Vmax of FPP
synthase (1.08 mmol/min/mg prot) [39] is higher than the Vmax of
GGPP synthase (0.24 mmol/min/mg prot) [40], that can represent a
limitating factor for RhoA geranylgeranylation. When atorvastatin
further lowered the amount of GGPP, the activation of RhoA may be
hampered much more than the activation of Ras. Similarly Kcat of
farnesyl transferase (0.09 s1) [41] is higher than Kcat of
geranylgeranyl transferase (0.02 s1) [42]. In the presence of a
decreased amount of substrates, as occurred with atorvastatin, it is
expected that the less efﬁcient enzyme, i.e. geranylgeranyl
transferase, would be more affected.
Taken together, our data depict two scenarios in Her2-positive
cells exposed to statin: at low micromolar concentrations,
atorvastatin did not reduce the activity of Ras/ERK1/2 pathway
and up-regulated the IKK/NF-kB pathway; at high micromolar
concentrations, atorvastatin was able to decrease the activation of
Ras-dependent pathways, but simultaneously maintained NF-kB
active. The latter scenario occurred in animals treated with
atorvastatin, since in their mammary glands Ras/ERK1/2 pathway
resulted as suppressed, while NF-kB signaling resulted as
activated.
Besides preserving mammary cells trophism, NF-kB up-
regulates several genes involved in the inhibition of apoptosis
and/or in cell proliferation (such as Bcl2, Bcl-xl, cyclin D1, cyclin
D2, c-Myc, c-Myb) and increases the synthesis of cytokines and
growth factors, which sustain tumor proliferation and progres-
sion with autocrine mechanisms [28]. These mechanisms may
explain why atorvastatin was not able to elicit any antiproli-
ferative effect in mammary tumors of BALB-neuT mice, although
it turned down Her2-dependent proliferation signals. Only if weprevented the activation of NF-kB with parthenolide, did the
statin become able to reduce cell proliferation at lower
concentrations, sufﬁcient to decrease Ras-dependent signaling.
Interestingly also parthenolide alone reduced TUBO cell prolif-
eration, suggesting that NF-kB has a strong and autonomous role
in sustaining the growth of Her2-positive cells. Such hypothesis
is in accordance with previous observations reporting that IKKa
regulates the proliferation of mammary cells and plays a pivotal
role in the carcinogenesis of Her2/neu-positive mammary
tumors [43].
In summary our work underlines that in Her2-positive cancers
the Her2-dependent pathways could be not the only signals
important for cell proliferation, but other Her2-independent
mechanisms can critically sustain tumor growth in cooperation
with Her2 oncogene. Such a redundancy of pro-proliferative
signals may explain the aggressive phenotype of Her2-over-
expressing tumors, a feature frequently observed in clinical
practice.
Furthermore we have shown that statins can contemporane-
ously modulate multiple signaling pathways in Her2-positive
cancer cells: such pleiotropism, which in other contexts has made
statin drugs potentially useful in several diseases, may paradoxi-
cally dissipate the expected beneﬁcial effects of HMGCoAR
inhibitors in terms of antiproliferative activity. The identiﬁcation
of the pathways controlled by statins in each tumor is mandatory,
in order to take advantage of the use of these drugs in association
with other tumor-speciﬁc and selective targeted therapies. In this
perspective the association of atorvastatin and NF-kB inhibitors
may be regarded as a potential new therapeutic approach in Her2-
positive tumors, with results often refractory to conventional
anticancer therapies.
Fig. 8. Effective inhibition of TUBO cells proliferation by associating atorvastatin
and parthenolide. Cells were cultured 24 h in fresh medium (CTRL) or in medium
containing atorvastatin (50 mM, AT), in the absence or presence of the inhibitor of
NF-kB parthenolide (10 mM, PART). A. NF-kB activation. The activity of NF-kB was
detected in the nuclear extracts using a DNA binding assay as reported previously.
Measurements were performed in duplicate and data are presented as means  SE
(n = 3). vs. CTRL: *p < 0.005; vs. AT: 8p < 0.005. B. Proliferation of TUBO cells was
measured by the BrdU assay, as described in Section 2. Measurements were performed
in quadruplicate and data are presented as mean  SE (n = 3). vs. CTRL: *p < 0.02; vs.
AT: 8p < 0.05.
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